Literature DB >> 22032839

Cyclosporine A suppresses immunoglobulin G biosynthesis via inhibition of cyclophilin B in murine hybridomas and B cells.

Jisun Lee1, Tae Gyu Choi, Joohun Ha, Sung Soo Kim.   

Abstract

Immunoglubulin G (IgG) is a major isotype of antibody, which is predominantly involved in immune response. The complete tetramer is needed to fold and assemble in endoplasmic reticulum (ER) prior to secretion from cells. Protein quality control guided by ER chaperons is most essential for full biological activity. Cyclophilin B (CypB) was initially identified as a high-affinity binding protein for the immunosuppressive drug Cyclosporine A (CsA). CsA suppresses organ rejection by halting productions of pro-inflammatory molecules in T cell and abolishes the enzymatic property of CypB that accelerates the folding of proteins by catalysing the isomerization of peptidyl-proline bonds in ER. Here, we reported that CsA significantly inhibited IgG biosynthesis at posttranslational level in antibody secreting cells. Moreover, CsA stimulated the extracellular secretion of CypB and induced ROS generation, leading to expressions of ER stress markers. In addition, the absence of intracellular CypB impaired the formation of ER multiprotein complex, which is most important for resisting ER stress. Interestingly, CsA interrupted IgG folding via occupying the PPIase domain of CypB in ER. Eventually, unfolded IgG is degraded via Herp-dependent ERAD pathway. Furthermore, IgG biosynthesis was really abrogated by inhibition of CypB in primary B cells. We established for the first time the immunosuppressive effect of CsA on B cells. Conclusively, the combined results of the current study suggest that CypB is a pivotal molecule for IgG biosynthesis in ER quality control.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22032839     DOI: 10.1016/j.intimp.2011.10.007

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  8 in total

Review 1.  Unraveling the regulatory role of endoplasmic-reticulum-associated degradation in tumor immunity.

Authors:  Xiaodan Qin; William D Denton; Leah N Huiting; Kaylee S Smith; Hui Feng
Journal:  Crit Rev Biochem Mol Biol       Date:  2020-07-07       Impact factor: 8.250

2.  Human structural proteome-wide characterization of Cyclosporine A targets.

Authors:  Gang Hu; Kui Wang; Jody Groenendyk; Khaled Barakat; Marcin J Mizianty; Jishou Ruan; Marek Michalak; Lukasz Kurgan
Journal:  Bioinformatics       Date:  2014-08-28       Impact factor: 6.937

Review 3.  Intrathecal IgG synthesis: a resistant and valuable target for future multiple sclerosis treatments.

Authors:  Mickael Bonnan
Journal:  Mult Scler Int       Date:  2015-01-08

4.  Cyclosporine A binding to COX-2 reveals a novel signaling pathway that activates the IRE1α unfolded protein response sensor.

Authors:  Jody Groenendyk; Tautvydas Paskevicius; Hery Urra; Clement Viricel; Kui Wang; Khaled Barakat; Claudio Hetz; Lukasz Kurgan; Luis B Agellon; Marek Michalak
Journal:  Sci Rep       Date:  2018-11-12       Impact factor: 4.379

5.  FK506-Binding Protein 11 Is a Novel Plasma Cell-Specific Antibody Folding Catalyst with Increased Expression in Idiopathic Pulmonary Fibrosis.

Authors:  Stefan Preisendörfer; Yoshihiro Ishikawa; Elisabeth Hennen; Stephan Winklmeier; Jonas C Schupp; Larissa Knüppel; Isis E Fernandez; Leonhard Binzenhöfer; Andrew Flatley; Brenda M Juan-Guardela; Clemens Ruppert; Andreas Guenther; Marion Frankenberger; Rudolf A Hatz; Nikolaus Kneidinger; Jürgen Behr; Regina Feederle; Aloys Schepers; Anne Hilgendorff; Naftali Kaminski; Edgar Meinl; Hans Peter Bächinger; Oliver Eickelberg; Claudia A Staab-Weijnitz
Journal:  Cells       Date:  2022-04-14       Impact factor: 7.666

6.  TMUB1 Inhibits BRL-3A Hepatocyte Proliferation by Interfering with the Binding of CAML to Cyclophilin B through its TM1 Hydrophobic Domain.

Authors:  Xiang Lan; Hangwei Fu; Guangyao Li; Wei Zeng; Xia Lin; Yuanxin Zhu; Menggang Liu; Ping Chen
Journal:  Sci Rep       Date:  2018-07-02       Impact factor: 4.379

Review 7.  Targeting FcRn for immunomodulation: Benefits, risks, and practical considerations.

Authors:  Hans-Hartmut Peter; Hans D Ochs; Charlotte Cunningham-Rundles; Donald C Vinh; Peter Kiessling; Bernhard Greve; Stephen Jolles
Journal:  J Allergy Clin Immunol       Date:  2020-09       Impact factor: 10.793

8.  Cyclophilin B overexpression predicts a poor prognosis and activates metastatic pathways in colon cancer.

Authors:  Xiaojing Zhang; Jinjing Tan; Lei Yang; Guangyu An
Journal:  Transl Cancer Res       Date:  2020-05       Impact factor: 1.241

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.